Dexcom (DC4) Stock Price & Analysis
DC4 Stock Chart & Stats
- Day’s Range
- EUR 72.80 - EUR 75.40
- 52-Week Range
- EUR 47.00 - EUR 79.60
- Previous Close
- EUR 70.80
- Volume
- 0
- Average Volume (3M)
- 46
- Market Cap
- EUR 27.39B
- Enterprise Value
- EUR 32.67B
- Total Cash (Recent Filing)
- EUR 1.82B
- Total Debt (Recent Filing)
- EUR 1.39B
- Price to Earnings (P/E)
- 31.8
- Beta
- 1.03
- Next Earnings
- Feb 11, 2027 (Est.)
- EPS Estimate
- 0.64
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring CGM Revenue
Dexcom’s sensor replacement cycle creates recurring revenue and supports customer retention after initial adoption. This model provides a durable base for forecasting, while ongoing reimbursement, channel access, and connected-care partnerships can expand utilization and deepen the value of each customer relationship.
Revenue And Margin Expansion
Strong revenue growth alongside high gross and net margins indicates meaningful operating scale and a profitable business model. Continued margin expansion would increase internal funding for product development, international expansion, and digital initiatives while strengthening Dexcom’s ability to compete over the next several quarters.
Market Share And Clinical Strength
Share gains across customer segments, supported by strong clinical evidence, reinforce Dexcom’s product credibility with patients, clinicians, and reimbursement bodies. This combination can support durable adoption, broaden use among type 2 customers, and strengthen the company’s competitive position in CGM.
Bears Say
Weaker Cash Conversion
Recent deterioration in cash conversion means reported earnings are translating into less incremental cash than before. Although absolute cash generation remains substantial, higher investment or working-capital needs could reduce funding available for expansion, buybacks, and other capital-allocation priorities.
Slower International Growth
Slower international growth creates a drag on consolidated expansion and shows that reimbursement-driven gains may not repeat evenly across markets. A prolonged normalization period could delay the benefits of global scale, limit geographic diversification, and require continued investment to rebuild adoption momentum.
Preferred PBM Access Loss
Loss of preferred access can raise patient costs and make Dexcom’s products less attractive for affected members, creating friction in new starts and retention. Even with a limited direct revenue exposure, the issue increases reliance on alternative pathways such as medical benefits and Dexcom Direct.
DC4 FAQ
What was Dexcom’s price range in the past 12 months?
What is Dexcom’s market cap?
When is Dexcom’s upcoming earnings report date?
How were Dexcom’s earnings last quarter?
Is Dexcom overvalued?
Does Dexcom pay dividends?
What is Dexcom’s EPS estimate?
How many shares outstanding does Dexcom have?
What happened to Dexcom’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Dexcom?
What is the TipRanks Smart Score and how is it calculated?
Dexcom Stock Smart Score
Company Description
Dexcom
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach
- Employees
- 11,050
- Website
- www.dexcom.com
- Address
- 6340 Sequence Drive, San Diego, CA, 92121, US
Dexcom (DC4) Earnings & Revenues
DC4 Company Deck
DC4 Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Dexcom reported 11% worldwide revenue growth, 14% U.S. growth, continued market-share gains, near-record new patient starts, significant gross-margin and EBITDA-margin expansion, strong cash generation, raised operating and EBITDA margin guidance, and substantial progress in clinical evidence, product launches, manufacturing, and future access expansion. The main challenges were slower international growth, near-term Ireland ramp effects, incremental foreign-exchange headwinds, higher operating expenses, and the loss of preferred access under a PBM representing less than 4% of U.S. revenue. Highlights significantly outweighed the lowlights.
View all DE:DC4 earnings summariesDC4 Net sales Breakdown
- 71.53% U.S.
- 28.47% International
DC4 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 6 | 2 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 11 | 0 | 1 |